SBIO / Consolidation Could Come Calling for Biotech in 2022

Biotechnology is certainly on the list, if not at the top, of high-growth industries in dire need of a rebound. Following enthusiasm for COVID-19 vacc more_horizontal

One of the long-running catalysts for small- and mid-sized biotechnology companies is the possibility that they'll eventually be acquired by large-cap more_horizontal

ETFs offering biotech exposure are rallying on Monday, lifted by a significant M&A announcement in the industry. The ALPS Medical Breakthroughs ETF more_horizontal

With technology ETFs taking in $3.2 billion over one month, compared to overall -$4 billion in YTD outflows according to YCharts, investors are lookin more_horizontal

The ALPS Medical Breakthroughs ETF (SBIO) rallied 11.53% last week on positive trial data and merger and acquisition news that revived the biotech sec more_horizontal

Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of more_horizontal

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy t more_horizontal

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose more_horizontal